Dianthus Therapeutics, Inc. (DNTH)
NASDAQ: DNTH · Real-Time Price · USD
27.75
-0.37 (-1.32%)
Oct 29, 2024, 4:00 PM EDT - Market closed

Company Description

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases.

It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.

Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

Dianthus Therapeutics, Inc.
Dianthus Therapeutics logo
Country United States
Founded 2015
Industry Biotechnology
Sector Healthcare
Employees 53
CEO Marino Garcia

Contact Details

Address:
7 Times Square, 43rd Floor
New York, New York 10036
United States
Phone 929 999 4055
Website dianthustx.com

Stock Details

Ticker Symbol DNTH
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001690585
CUSIP Number 252828108
ISIN Number US2528281080
SIC Code 2834

Key Executives

Name Position
Marino Garcia M.B.A. President, Chief Executive Officer, Secretary and Director
Ryan Savitz Chief Financial Officer and Chief Business Officer and Treasurer
Simrat Randhawa M.B.A., M.D. Chief Medical Officer
Edward G. Carr Chief Accounting Officer
Judson Taylor Head of Technical Operations
Dr. Jeffrey Stavenhagen Ph.D. Chief Scientific Officer
Jennifer Davis Ruff Vice President and Head of Investor Relations and Corporate Affairs.
Adam M. Veness Esq. Senior Vice President, General Counsel and Secretary
Kristina Maximenko Chief People Officer
Rashieda Gluck Head of Clinical Development Operations

Latest SEC Filings

Date Type Title
Oct 24, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Oct 21, 2024 RW Filing
Oct 11, 2024 424B5 Filing
Oct 11, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Oct 11, 2024 424B3 Prospectus
Oct 9, 2024 EFFECT Notice of Effectiveness
Oct 9, 2024 EFFECT Notice of Effectiveness
Oct 1, 2024 S-3 Registration statement under Securities Act of 1933
Oct 1, 2024 S-3 Registration statement under Securities Act of 1933
Sep 16, 2024 424B3 Prospectus